Vivaldi Coelho Rogerio
Director at CRNX; Chief Commercial Officer at Spark Therapeutics, Inc.
- Sold, on record
- $4.1M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Jul 2, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- CRNXCrinetics Pharmaceuticals, Inc.Director
- Spark Therapeutics, Inc.Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Spark Therapeutics, Inc.79,000 shares
- CRNX8,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Spark Therapeutics, Inc.UnusualOct 7, 2015 2015
Sold 41,000 shares at $48.85 ($2M)
Vivaldi Coelho Rogerio, Chief Commercial Officer
Sold 88.4% of holdings ($2.3M position)5,383 shares leftFirst sale on recordFiling
- 2 Form 4 sale Spark Therapeutics, Inc.UnusualOct 13, 2015 +6 days
Sold 24,000 shares at $48.15 ($1.2M)
Vivaldi Coelho Rogerio, Chief Commercial Officer
Sold 56.2% of holdings ($2.1M position)18,716 shares leftFiling
- 3 Form 4 sale Spark Therapeutics, Inc.UnusualApr 21, 2016 +191 days
Sold 7,000 shares at $40.02 ($280k)
Vivaldi Coelho Rogerio, Chief Commercial Officer
Sold 27.2% of holdings ($1M position)18,716 shares leftFiling
- 4 Form 4 sale Spark Therapeutics, Inc.UnusualJul 15, 2016 +85 days
Sold 7,000 shares at $53.03 ($371k)
Vivaldi Coelho Rogerio, Chief Commercial Officer
Sold 27.2% of holdings ($1.4M position)18,716 shares left0.3x usual sizeFiling
- 5 Form 4 sale CRNXRoutineMar 12, 2026 +3527 days
Sold 5,000 shares at $36.15 ($181k)
Vivaldi Coelho Rogerio, Director
10b5-1 planSold 23.5% of holdings ($770k position)16,300 shares leftFirst sale on recordFiling
- 6 Form 4 sale CRNXRoutineJul 2, 2026 +112 days
Sold 3,000 shares at $40.00 ($120k)
Vivaldi Coelho Rogerio, Director
10b5-1 planSold 13.5% of holdings ($889k position)19,225 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Jul 7, 2026 | CRNX | Director | Form 4 sale | 3,000 | $120k | 13.5% | Routine | SEC |
| Mar 12, 2026 | Mar 13, 2026 | CRNX | Director | Form 4 sale | 5,000 | $181k | 23.5% | Routine | SEC |
| Jul 15, 2016 | Jul 19, 2016 | Spark Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 7,000 | $371k | 27.2% | Unusual | SEC |
| Apr 21, 2016 | Apr 22, 2016 | Spark Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 7,000 | $280k | 27.2% | Unusual | SEC |
| Oct 13, 2015 | Oct 14, 2015 | Spark Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 24,000 | $1.2M | 56.2% | Unusual | SEC |
| Oct 7, 2015 | Oct 9, 2015 | Spark Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 41,000 | $2M | 88.4% | Unusual | SEC |